Brown Brothers Harriman & Co’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-6,255
Closed -$17.1K 1600
2025
Q1
$17.1K Hold
6,255
﹤0.01% 982
2024
Q4
$26K Hold
6,255
﹤0.01% 980
2024
Q3
$24.3K Hold
6,255
﹤0.01% 912
2024
Q2
$24.5K Hold
6,255
﹤0.01% 862
2024
Q1
$26.2K Hold
6,255
﹤0.01% 858
2023
Q4
$29.4K Hold
6,255
﹤0.01% 793
2023
Q3
$19.5K Hold
6,255
﹤0.01% 848
2023
Q2
$28.7K Hold
6,255
﹤0.01% 793
2023
Q1
$31K Hold
6,255
﹤0.01% 816
2022
Q4
$34.2K Hold
6,255
﹤0.01% 785
2022
Q3
$41K Buy
+6,255
New +$34.9K ﹤0.01% 782

Other funds holding MXCT

Brown Brothers Harriman & Co's MXCT Position: Q2 2025 in Review

Brown Brothers Harriman & Co sold out of MaxCyte (MXCT) in Q2 2025, closing a stake of 6,255 shares — an estimated $17.1K sold.

Brown Brothers Harriman & Co first reported a position in MXCT in Q3 2022 and held it in 11 quarters. The position peaked at $41K in Q3 2022. 120 funds tracked by Wall St. Rank hold MXCT as of Q2 2025.

  • Brown Brothers Harriman & Co reported no remaining MaxCyte position as of Q2 2025 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 6,255 MaxCyte shares in Q2 2025, an estimated $17.1K.
  • Brown Brothers Harriman & Co first reported a position in MaxCyte in Q3 2022 and held it in 11 quarters.
  • Brown Brothers Harriman & Co's MaxCyte position peaked at $41K in Q3 2022.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q2 2025.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2025, filed 11 Aug 2025.